MergerJun 9, 2026, 04:07 PM
Esperion Merger with ArchiMed Affiliate Cleared by German Antitrust
AI Summary
Esperion Therapeutics announced that the Bundeskartellamt, the German antitrust authority, has cleared its previously disclosed merger with Essence Parent Inc., an affiliate of ArchiMed SAS. This clearance, effective June 2, 2026, satisfies one of the key conditions for the merger. The completion of the merger is still contingent upon other closing conditions, including the expiration of waiting periods under the Hart-Scott-Rodino Antitrust Improvement Act and the adoption of the Merger Agreement by Esperion's stockholders at a meeting scheduled for July 8, 2026.
Key Highlights
- Bundeskartellamt cleared Esperion's merger with Essence Parent Inc., effective June 2, 2026.
- Esperion Therapeutics, Inc. will merge with Essence MergerCo Inc., a subsidiary of Essence Parent Inc.
- Esperion will become a wholly-owned subsidiary of Essence Parent Inc., an affiliate of ArchiMed SAS.
- The merger remains subject to the expiration of Hart-Scott-Rodino Act waiting periods.
- Stockholder approval is also required for the merger to be completed.
- A special meeting for stockholders to consider the merger is scheduled for July 8, 2026.
Price Impact
More from ESPR